Sfoglia per AUTORE
GALLI F
Collezione AO Ordine Mauriziano
Items : 2
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2024 Sep;25(9):1135-1146. doi: 10.1016/S1470-2045(24)00334-6. Epub 2024 Aug 2.
2024
AO Ordine Mauriziano
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU Città della Salute di Torino
Barretina Ginesta MP; Uggeri S; Rulli E; Laudani ME; Lissoni AA; Petrella M; Tognon G; Ferrero A; Manso L; Takehara K; Tasca G; Zamagni C; McQueen J; Nakagawa S; Piovano E; Pardo B; Lee YC; Nishio S; Allan K; Fariñas-Madrid L; Parma G; Marth C; Marmé F; Rabaglio M; Antill Y; Choi CH; Hudson E; Galli F; Harano K; et alii...
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer. in British journal of cancer / Br J Cancer. 2019 Oct;121(9):744-750. doi: 10.1038/s41416-019-0584-5. Epub 2019 Sep 20.
2019
AO Ordine Mauriziano
AO Ordine Mauriziano
Colombo N; Zaccarelli E; Baldoni A; Frezzini S; Scambia G; Palluzzi E; Tognon G; Lissoni AA; Rubino D; Ferrero A; Farina G; Negri E; Pesenti Gritti A; Galli F; Biagioli E; Rulli E; Poli D; Gerardi C; Torri V; Fossati R; D'Incalci M;